Global Endometriosis Market 2025-2035

Endometriosis Market Size, Share & Trends Analysis Report by Drug Type (Gonadotropins Releasing Hormone Agonists, Non-Steroidal Anti-Inflammatory Drug, Progestin, and Oral Contraceptive Pills) by Diagnosis (Ultrasound, Pelvic Exam, Laparoscopy, Magnetic Resonance Imaging (MRI), Hysteroscopy, and Sonohysterography) by Treatment (Hormonal Therapy, and Pain Management), and Low-Power Wide-Area Network (LPWAN)) and by Distribution Channel (Hospital, Drug Stores, Retail Pharmacies, Mail Order Pharmacies, and E-Commerce ) Forecast Period (2025-2035)

Industry Overview

Endometriosis market was valued at $1.8 billion in 2024 and is projected to reach $6.2 billion by 2035, growing at a CAGR of 11.9% during the forecast period (2025–2035). The global endometriosis treatment market is experiencing rapid growth, driven by increasing disease prevalence, rising patient awareness, and advancements in diagnostic and therapeutic technologies, including non-hormonal and minimally invasive options. Key market drivers include greater governmental focus on women's health and funding for research, but challenges persist in the form of high treatment costs, reimbursement hurdles, and the need for more accurate diagnostic tools.

Market Dynamics

Rising Prevalence of Endometriosis and Growing Awareness

The global endometriosis market is primarily driven by the increasing prevalence of the disease among women of reproductive age. Studies indicate that approximately 10% of women worldwide are affected by endometriosis, often leading to chronic pelvic pain, infertility, and reduced quality of life. Growing awareness among women, healthcare providers, and advocacy groups about the symptoms and impact of the condition has led to earlier diagnosis and treatment. Awareness campaigns, educational programs, and social media initiatives have empowered patients to seek medical attention, boosting demand for effective therapies and diagnostic solutions.

Advancements in Diagnostic Techniques

Another key driver supporting market growth is the development and adoption of advanced diagnostic technologies. Traditional methods like pelvic exams and ultrasounds are now supplemented with laparoscopic procedures, magnetic resonance imaging (MRI), hysteroscopy, and sonohysterography, which provide more accurate and early detection of endometriosis. Early diagnosis is critical in managing the disease effectively, reducing complications, and improving patient outcomes. Healthcare providers are increasingly investing in these sophisticated diagnostic tools, which in turn stimulates demand for associated treatments and follow-up care.

Development of Targeted and Hormonal Therapies

Pharmaceutical innovation is a significant driver of the endometriosis market. Companies are focusing on developing targeted therapies and hormonal treatments, including gonadotropin-releasing hormone (GnRH) agonists, progestins, and oral contraceptive pills, that are effective in managing pain, reducing lesion growth, and improving fertility outcomes. New drug formulations offering improved efficacy, reduced side effects, and convenient administration methods, such as oral pills or injectables, are expanding treatment adoption. Additionally, ongoing clinical trials and research into novel therapies are expected to sustain long-term market growth by offering better options for patients who do not respond to conventional treatments.

Market Segmentation

• Based on the drug type, the market is segmented into gonadotropin-releasing hormone agonists, non-steroidal anti-inflammatory drugs, progestins, and oral contraceptive pills.
• Based on the diagnosis, the market is segmented into ultrasound, pelvic exam, laparoscopy, magnetic resonance imaging (MRI), hysteroscopy, and sonohysterography.
• Based on the treatment, the market is segmented into hormonal therapy and pain management.
• Based on the distribution channel, the market is segmented into hospitals, drug stores, retail pharmacies, mail order pharmacies, and e-commerce.

Hormonal Therapy Largest Segment Leading the Global Endometriosis Market

Among all segments in the global endometriosis market, hormonal therapy holds the largest share and is the leading segment. Hormonal therapy includes the use of oral contraceptive pills, progestins, and gonadotropin-releasing hormone (GnRH) agonists, which work by suppressing or regulating hormone levels to reduce the growth of endometrial tissue and alleviate pain. This segment dominates due to its widespread adoption among patients and healthcare providers, proven efficacy, and well-established clinical guidelines supporting its use. Hormonal therapy not only addresses pain management but also helps prevent recurrence after surgical interventions, making it the preferred treatment choice for long-term management of endometriosis.

Laparoscopy: A Key Segment in Market Growth

In terms of diagnosis, laparoscopy remains a significant tool, as it is considered the gold standard for confirming endometriosis. While imaging techniques such as ultrasound and MRI are gaining traction due to their non-invasive nature, laparoscopy remains vital for accurate staging of the disease and guiding treatment decisions. The combination of improved diagnostic techniques and the increasing preference for minimally invasive procedures is enhancing early detection, which in turn stimulates demand for effective drug therapies, such as GnRH agonists.

Regional Outlook

The global endometriosis industry is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Maintains Strong Market Position

North America holds a significant share of the global Endometriosis market. North America, particularly the US, dominates the global endometriosis market, holding a major share in terms of market size and growth. The strong position of the US market can be attributed to several factors, including high healthcare expenditure, advanced medical infrastructure, and widespread awareness about women’s health issues. The presence of well-established pharmaceutical companies, such as AbbVie, Pfizer, and Takeda, actively involved in the research and development of innovative endometriosis therapies, further strengthens the market dominance.

The US benefits from a well-structured healthcare system that supports early diagnosis and effective management of endometriosis. Diagnostic technologies such as laparoscopy, MRI, and ultrasound are widely accessible, enabling the timely identification and treatment of the disease. Additionally, growing awareness campaigns and patient advocacy programs have educated women about the symptoms and long-term impacts of endometriosis, driving early medical intervention and increasing demand for hormonal therapies, GnRH agonists, and other treatment options. Moreover, the regulatory environment in the US is favorable for the introduction of novel therapies. Recent approvals of oral GnRH antagonists and combination hormonal therapies have expanded treatment options, improving patient adherence and outcomes. E-commerce and retail pharmacy networks further facilitate easy access to medications, enhancing market reach.

Market Players Outlook

The major companies operating in the global endometriosis market include AbbVie Inc., AstraZeneca plc, Bayer AG, Pfizer Inc., and Takeda Pharmaceutical Co., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In July 2025, Organon released its Phase 2 ELENA study evaluating the oral HSD17B1 inhibitor OG-6219 for endometriosis-related pain did not meet its primary efficacy endpoint, showing no improvement in pelvic pain compared to placebo. Consequently, the company will discontinue the clinical development program for OG-6219. The double-blind, placebo-controlled study involved pre-menopausal women aged 18 to 49 with moderate-to-severe endometriosis-related pain, assessing efficacy over three treatment cycles using a numerical pain rating scale.

The Report Covers

• Market value data analysis of 2024 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global endometriosis market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.

Show more